Early alterations in energy metabolism in the hippocampus of APPswe/PS1dE9 mouse model of Alzheimer's disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 9, 2014, Pages 1556-1566

  Pedrós, Ignacio ^b,c,g   Petrov, Dmitry ^a,c,g   Allgaier, Michael ^a,c,g   Sureda, Francesc ^b,c,g   Barroso, Emma ^a,d,g   Beas Zarate, Carlos ^e,f,g   Auladell, Carme ^a,g   Pallàs, Mercè ^a,c,g   Vázquez Carrera, Manuel ^a,d,g   Casadesús, Gemma ^e,g   Folch, Jaume ^b,c,g   Camins, Antoni ^a,c,g  

^a UNIVERSITY OF BARCELONA   (Spain)

^b FACULTAT DE MEDICINA I CIÈNCIES DE LA SALUT   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f CENTRO DE INVESTIGACIÓN BIOMÉDICA DE OCCIDENTE   (Mexico)

^g CUCBA   (Mexico)

Author keywords

Alzheimer's disease; APPswe PS1dE9; Hippocampus; Insulin receptor; Mitochondria; Tau

Indexed keywords

AMP ACTIVATED PROTEIN KINASE ALPHA 1; AMP ACTIVATED PROTEIN KINASE ALPHA 2; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; CYCLIN DEPENDENT KINASE 5; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3BETA; HUMAN INSULIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; MESSENGER RNA; MITOCHONDRIAL TRANSCRIPTION FACTOR A; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PREPROINSULIN; PREPROINSULIN 1; PROTEIN FOS; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR; SYNAPTOPHYSIN; TAU PROTEIN; TRANSCRIPTION FACTOR NRF1; TRANSCRIPTION FACTOR NRF2; TRANSFERRIN BINDING PROTEIN; UNCLASSIFIED DRUG; BRAIN EXTRACT; SOMATOMEDIN;

ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CELL ENERGY; COGNITIVE DEFECT; CONTROLLED STUDY; DOWN REGULATION; ENERGY METABOLISM; ENZYME LINKED IMMUNOSORBENT ASSAY; ESSENTIAL GENE; GENE EXPRESSION; GENE REPLICATION; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; HIPPOCAMPUS; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; INSULIN METABOLISM; INSULIN TOLERANCE TEST; MALE; MEMORY; MITOCHONDRIAL RESPIRATION; MOUSE; MOUSE MODEL; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; WESTERN BLOTTING; AMYLOID PLAQUE; BIOGENESIS; HUMAN; IMMUNOBLOTTING; MITOCHONDRION; RESPIRATORY FUNCTION;

ALZHEIMER'S DISEASE; APPSWE/PS1DE9; HIPPOCAMPUS; INSULIN RECEPTOR; MITOCHONDRIA; TAU;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOIDOGENIC PROTEINS; ANIMALS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIPPOCAMPUS; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MITOCHONDRIA; PRESENILIN-1; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84903702536     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.05.025     Document Type: Article

References (73)

1. Smith M.A. Alzheimer disease. Int. Rev. Neurobiol. 1998, 42:1-54.
2. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
3. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
4. Erol A. An integrated and unifying hypothesis for the metabolic basis of sporadic Alzheimer's disease. J. Alzheimers Dis. 2008, 13:241-253.
5. Swerdlow R.H., Khan S.M. A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. Med. Hypotheses 2004, 63:8-20.
6. Bassil N., Grossberg G.T. Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease. CNS Drugs 2009, 23:293-307.
7. Swerdlow R.H. Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer's disease. Antioxid. Redox Signal. 2012, 16:1434-1455.
8. Zhang W., Hao J., Liu R., Zhang Z., Lei G., Su C., Miao J., Li Z. Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease. Behav. Brain Res. 2011, 222:342-350.
9. Selfridge J.E., Lu J., Swerdlow R.H. Role of mitochondrial homeostasis and dynamics in Alzheimer's disease. Neurobiol. Dis. 2013, 51:3-12.
10. Pimplikar S.W. Reassessing the amyloid cascade hypothesis of Alzheimer's disease. Int. J. Biochem. Cell Biol. 2009, 41:1261-1268.
11. Pimplikar S.W., Nixon R.A., Robakis N.K., Shen J., Tsai L.H. Amyloid-independent mechanisms in Alzheimer's pathogenesis. J. Neurosci. 2010, 30:14946-14954.
12. Zhang W., Bai M., Xi Y., Hao J., Liu L., Mao N., Su C., Miao J., Li Z. Early memory deficits precede plaque deposition in APPswe/PS1dE9 mice: involvement of oxidative stress and cholinergic dysfunction. Free Radic. Biol. Med. 2012, 52:1443-1452.
13. Sato N., Morishita R. Plasma β-amyloid: a possible missing link between Alzheimer disease and diabetes. Diabetes 2013, 62:1005-1006.
14. Zhang W., Bai M., Xi Y., Hao J., Zhang Z., Su C., Lei G., Miao J., Li Z. Multiple inflammatory pathways are involved in the development and progression of cognitive deficits in APPswe/PS1dE9 mice. Neurobiol. Aging 2012, 33:2661-2677.
15. De Felice F.G. Alzheimer's disease and insulin resistance: translating basic science into clinical applications. J. Clin. Invest. 2013, 123:531-539.
16. Jiménez-Palomares M., Ramos-Rodríguez J.J., López-Acosta J.F., Pacheco-Herrero M., Lechuga-Sancho A.M., Perdomo G., García-Alloza M., Cózar-Castellano I. Increased Aβ production prompts the onset of glucose intolerance and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 2012, 302:E1373-E1380.
17. Haataja L., Gurlo T., Huang C.J., Butler P.C. Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr. Rev. 2008, 29:303-316.
18. Zhang Y., Zhou B., Zhang F., Wu J., Hu Y., Liu Y., Zhai Q. Amyloid-β induces hepatic insulin resistance by activating JAK2/STAT3/SOCS-1 signaling pathway. Diabetes 2012, 61:1434-1443.
19. de la Monte S.M. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr. Alzheimer Res. 2012, 9:35-66.
20. Leal M.C., Magnani N., Villordo S., Buslje C.M., Evelson P., Castaño E.M., Morelli L. Transcriptional regulation of insulin-degrading enzyme modulates mitochondrial amyloid β (Aβ) peptide catabolism and functionality. J. Biol. Chem. 2013, 288:12920-12931.
21. de la Monte S.M. Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. Drugs 2012, 72:49-66.
22. de la Monte, Wands J.R. Alzheimer's disease is type 3 diabetes-evidence reviewed. J. Diabetes Sci. Technol. 2008, 2:1101-1113.
23. Trueba-Sáiz A., Cavada C., Fernandez A.M., Leon T., González D.A., Fortea Ormaechea J., Lleó A., Del Ser T., Nuñez A., Torres-Aleman I. Loss of serum IGF-I input to the brain as an early biomarker of disease onset in Alzheimer mice. Transl. Psychiatry Dec 3 2013, 3:e330.
24. Wang X., Zheng W., Xie J.W., Wang T., Wang S.L., Teng W.P., Wang Z.Y. Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model. Mol. Neurodegener. 2010, 2:46.
25. Sato N., Morishita R. Roles of vascular and metabolic components in cognitive dysfunction of Alzheimer disease: short- and long-term modification by non-genetic risk factors. Front. Aging Neurosci. 2013, 5:64.
26. van Exel E., Eikelenboom P., Comijs H., Deeg D.J., Stek M.L., Westendorp R.G. Insulin-like growth factor-1 and risk of late-onset Alzheimer's disease: findings from a family study. Neurobiol. Aging 2014, 35:725.e7-725.e10.
27. Steen E., Terry B.M., Rivera E.J., Cannon J.L., Neely T.R., Tavares R., Xu X.J., Wands J.R., de la Monte S.M. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes?. J. Alzheimers Dis. 2005, 7:63-80.
28. Farris W., Mansourian S., Chang Y., Lindsley L., Eckman E.A., Frosch M.P. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:4162-4167.
29. Takeda S., Sato N., Rakugi H., Morishita R. Molecular mechanisms linking diabetes mellitus and Alzheimer disease: beta-amyloid peptide, insulin signaling, and neuronal function. Mol. Biosyst. 2011, 7:1822-1827.
30. Takeda S., Sato N., Uchio-Yamada K., Sawada K., Kunieda T., Takeuchi D., Kurinami H., Shinohara M., Rakugi H., Morishita R. Elevation of plasma beta-amyloid level by glucose loading in Alzheimer mouse models. Biochem. Biophys. Res. Commun. 2009, 385:193-197.
31. Binukumar B.K., Zheng Y.L., Shukla V., Amin N.D., Grant P., Pant H.C. TFP5, a peptide derived from p35,a CDK5 neuronal activator, rescues cortical neurons from glucose toxicity. J. Alzheimers Dis. 2014, 39:899-909.
32. Hallows J.L., Chen K., DePinho R.A., Vincent I. Decreased cyclin-dependent kinase 5 (CDK5) activity is accompanied by redistribution of CDK5 and cytoskeletal proteins and increased cytoskeletal protein phosphorylation in p35 null mice. J. Neurosci. 2003, 23:10633-10644.
33. Takahashi M., Iseki E., Kosaka K. CDK5 and munc-18/p67 colocalization in early stage neurofibrillary tangles-bearing neurons in Alzheimer type dementia brains. J. Neurol. Sci. 2000, 172:63-69.
34. Alvira D., Ferrer I., Gutierrez-Cuesta J., Garcia-Castro B., Pallàs M., Camins A. Activation of the calpain/CDK5/p25 pathway in the girus cinguli in Parkinson's disease. Parkinsonism Relat. Disord. 2008, 14:309-313.
35. Camins A., Verdaguer E., Folch J., Canudas A.M., Pallàs M. The role of CDK5/P25 formation/inhibition in neurodegeneration. Drug News Perspect. 2006, 19:453-460.
36. Smith D.S., Tsai L.H. CDK5 behind the wheel: a role in trafficking and transport?. Trends Cell Biol. 2002, 12:28-36.
37. Bandyopadhyay S., Huang X., Lahiri D.K., Rogers J.T. Novel drug targets based on metallobiology of Alzheimer's disease. Expert Opin. Ther. Targets 2010, 14:1177-1197.
38. Blalock E.M., Chen K.C., Stromberg A.J., Norris C.M., Kadish I., Kraner S.D., Porter N.M., Landfield P.W. Harnessing the power of gene microarrays for the study of brain aging and Alzheimer's disease: statistical reliability and functional correlation. Ageing Res. Rev. 2005, 4:481-512.
39. Barabasi A.L., Oltvai Z.N. Network biology: understanding the cell's functional organization. Nat. Rev. Genet. 2004, 5:101-113.
40. Blalock E.M., Chen K.C., Sharrow K., Herman J.P., Porter N.M., Foster T.C., Landfield P.W. Gene microarrays in hippocampal aging: statistical profiling identifies novel processes correlated with cognitive impairment. J. Neurosci. 2003, 23:3807-3819.
41. Dou J.T., Chen M., Dufour F., Alkon D.L., Zhao W.Q. Insulin receptor signaling in long-term memory consolidation following spatial learning. Learn. Mem. 2005, 12:646-655.
42. Aso E., Lomoio S., López-González I., Joda L., Carmona M., Fernández-Yagüe N., Moreno J., Juvés S., Pujol A., Pamplona R., Portero-Otin M., Martín V., Díaz M., Ferrer I. Amyloid generation and dysfunctional immunoproteasome activation with disease progression in animal model of familial Alzheimer's disease. Brain Pathol. 2012, 22:636-653.
43. Barroso E., del Valle J., Porquet D., Vieira Santos A.M., Salvadó L., Rodríguez-Rodríguez R., Gutiérrez P., Anglada-Huguet M., Alberch J., Camins A., Palomer X., Pallàs M., Michalik L., Wahli W., Vázquez-Carrera M. Tau hyperphosphorylation and increased BACE1 and RAGE levels in the cortex of PPARβ/δ-null mice. Biochim. Biophys. Acta 2013, 1832:1241-1248.
44. Masliah E., Rockenstein E., Veinbergs I., Sagara Y., Mallory M., Hashimoto M., Mucke L. Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:12245-12250.
45. Dickey C.A., Gordon M.N., Mason J.E., Wilson N.J., Diamond D.M., Guzowski J.F., Morgan D. Amyloid suppresses induction of genes critical for memory consolidation in APP+PS1 transgenic mice. J. Neurochem. 2004, 88:434-442.
46. Hauptmann S., Scherping I., Dröse S., Brandt U., Schulz K.L., Jendrach M., Leuner K., Eckert A., Müller W.E. Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol. Aging 2009, 30:1574-1586.
47. Eckert A., Schulz K.L., Rhein V., Götz J. Convergence of amyloid-beta and tau pathologies on mitochondria in vivo. Mol. Neurobiol. 2010, 41:107-114.
48. Minkeviciene R., Ihalainen J., Malm T., Matilainen O., Keksa-Goldsteine V., Goldsteins G., Iivonen H., Leguit N., Glennon J., Koistinaho J., Banerjee P., Tanila H. Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild-type mice. J. Neurochem. 2008, 105:584-594.
49. Hiltunen M., Khandelwal V.K., Yaluri N., Tiilikainen T., Tusa M., Koivisto H., Krzisch M., Vepsäläinen S., Mäkinen P., Kemppainen S., Miettinen P., Haapasalo A., Soininen H., Laakso M., Tanila H. Contribution of genetic and dietary insulin resistance to Alzheimer phenotype in APP/PS1 transgenic mice. J. Cell. Mol. Med. 2012, 16:1206-1222.
50. Garcia-Alloza M., Robbins E.M., Zhang-Nunes S.X., Purcell S.M., Betensky R.A., Raju S., Prada C., Greenberg S.M., Bacskai B.J., Frosch M.P. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol. Dis. 2006, 24:516-524.
51. Hokama M., Oka S., Leon J., Ninomiya T., Honda H., Sasaki K., Iwaki T., Ohara T., Sasaki T., Laferla F.M., Kiyohara Y., Nakabeppu Y. Altered expression of diabetes-related genes in Alzheimer's disease brains: the Hisayama study. Cereb. Cortex 2013, in press. http://dx.doi.org/10.1093/cercor/bht101.
52. Ramos-Rodriguez J.J., Ortiz O., Jimenez-Palomares M., Kay K.R., Berrocoso E., Murillo-Carretero M.I., Perdomo G., Spires-Jones T., Cozar-Castellano I., Lechuga-Sancho A.M., Garcia-Alloza M. Differential central pathology and cognitive impairment in pre-diabetic and diabetic mice. Psychoneuroendocrinology 2013, 38:2462-2475.
53. Chua L.M., Lim M.L., Chong P.R., Hu Z.P., Cheung N.S., Wong B.S. Impaired neuronal insulin signaling precedes Aβ42 accumulation in female AβPPsw/PS1δE9 mice. J. Alzheimers Dis. 2012, 29:783-791.
54. Andersson U., Scarpulla R.C. Pgc-1-related coactivator, a novel, serum-inducible coactivator of nuclear respiratory factor 1-dependent transcription in mammalian cells. Mol. Cell. Biol. 2001, 21:3738-3749.
55. Finck B.N., Kelly D.P. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J. Clin. Invest. 2006, 116:615-622.
56. Sheng B., Wang X., Su B., Lee H.G., Casadesus G., Perry G., Zhu X. Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's disease. J. Neurochem. 2012, 120:419-429.
57. Katsouri L., Parr C., Bogdanovic N., Willem M., Sastre M. PARγ co-activator-1α (PGC-1α) reduces amyloid-β generation through a PPARγ-dependent mechanism. J. Alzheimers Dis. 2011, 25:151-162.
58. Shirwany N.A., Zou M.H. AMPK: a cellular metabolic and redox sensor. A minireview. Front. Biosci. (Landmark Ed.) 2014, 19:447-474.
59. Kim D., Nguyen M.D., Dobbin M.M., Fischer A., Sananbenesi F., Rodgers J.T., Delalle I., Baur J.A., Sui G., Armour S.M., Puigserver P., Sinclair D.A., Tsai L.H. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J. 2007, 26:3169-3179.
60. Qin W., Haroutunian V., Katsel P., Cardozo C.P., Ho L., Buxbaum J.D., Pasinetti G.M. PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia. Arch. Neurol. 2009, 66:352-361.
61. Galluzzi L., Blomgren K., Kroemer G. Mitochondrial membrane permeabilization in neuronal injury. Nat. Rev. Neurosci. 2009, 10:481-494.
62. Hoover B.R., Reed N.R.M., Jianjun S., Penrod R.D., Kotilinek L.A., Grant M.K., Pitstick R. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 2010, 6:1067-1081.
63. Shukla V., Skuntz S., Pant H.C. Deregulated CDK5 activity is involved in inducing Alzheimer's disease. Arch. Med. Res. 2012, 43:655-662.
64. Zhang L., Qingyang D., Zhao W. Nuclear respiratory factor 1 mediates the transcription initiation of insulin-degrading enzyme in a TATA box-binding protein-independent manner. PLoS One 2012, 8:e42035.
65. Gong C.X., Iqbal K. Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr. Med. Chem. 2008, 15:2321-2328.
66. Jucker M., Walker L.C. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 2013, 501:45-51.
67. Sadowski M., Pankiewicz J., Scholtzova H., Ji Y., Quartermain D., Jensen C.H., Duff K., Nixon R.A., Gruen R.J., Wisniewski T. Amyloid-beta deposition is associated with decreased hippocampal glucose metabolism and spatial memory impairment in APP/PS1 mice. J. Neuropathol. Exp. Neurol. 2004, 63:418-428.
68. Regev-Rudzki N., Pines O. Eclipsed distribution: a phenomenon of dual targeting of protein and its significance. Bioessays 2007, 29:772-782.
69. Vignini A., Giulietti A., Nanetti L., Raffaelli F., Giusti L., Mazzanti L., Provinciali L. Alzheimer's disease and diabetes: new insights and unifying therapies. Curr. Diabetes Rev. 2013, 9:218-227.
70. Yoshiyama Y., Lee V.M., Trojanowski J.Q. Therapeutic strategies for tau mediated neurodegeneration. J. Neurol. Neurosurg. Psychiatry 2013, 84:784-795.
71. Kopeikina K.J., Hyman B.T., Spires-Jones T.L. Soluble forms of tau are toxic in Alzheimer's disease. Transl. Neurosci. 2012, 3:223-233.
72. Ayala J.E., Samuel V.T., Morton G.J., Obici S., Croniger C.M., Shulman G.I., Wasserman D.H., McGuinness O.P. NIH Mouse Metabolic Phenotyping Center Consortium. Dis Model Mech. 2010, 3:525-534.
73. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987, 162:156-159.